- 英文名称
- RMC-9805
- 分子式
- C63H88F3N11O7
- 分子量
- 1168.44
- 中文别名
- (2S)-2-环戊基-2-((S)-7-((2R,3R)-3-环丙基-1-甲氧基氮丙啶-2-羰基)-2,7-二氮杂螺[4.4]壬烷-2-基)-N-((22S,63S,4S)-12-(5-(4-环丙基哌嗪-1-基)-2-((S)-1-甲氧基乙基)吡啶-3-基)-10,10-二甲基-5,7-二氧代-11-(2,2,2-三氟乙基)-61,62,63,64,65,66-六氢-11H-8-氧杂-2(4,2)-吗啉-1(5,3)吲哚-6(1,3)-哒嗪环十一烷-4-基)乙酰胺; KRAS G12D抑制剂18; RMI-9805; (2S)-2-环戊基-2-[(5S)-2-[(2R,3R)-3-环丙基-1-甲基氮杂环丙烷-2-羰基]-2,7-二氮杂螺[4.4]壬烷-7-基]-N-[(6S,8S,14S)-21-[5-(4-环丙基哌嗪-1-基)-2-[(1S)-1-甲氧基乙基]吡啶-3-基]-18,18-二甲基-9,15-二氧代-22-(2,2,2-三氟乙基)-5,16-二氧杂-2,10,22,28-四氮杂五环[18.5.2.12,6.110,14.023,27]二十九烷-1(26),20,23(27),24-四烯-8-基]乙酰胺; KRAS G12D inhibitor 18; RMI-5921; (2S)-2-Cyclopentyl-2-((S)-7-((2R,3R)-3-cyclopropyl-1-methylaziridine-2-carbonyl)-2,7-diazaspiro[4.4]nonan-2-yl)-N-((22S,63S,4S)-12-(5-(4-cyclopropylpiperazin-1-yl)-2-((S)-1-methoxyethyl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-11-(2,2,2-trifluoroethyl)-61,62,63,64,65,66-hexahydro-11H-8-oxa-2(4,2)-morpholina-1(5,3)-indola-6(1,3)-pyridazinacycloundecaphane-4-yl)acetamide; (2S)-2-cyclopentyl-2-[(5S)-7-[(2R,3R)-3-cyclopropyl-1-methylaziridine-2-carbonyl]-2,7-diazaspiro[4.4]nonan-2-yl]-N-[(6S,8S,14S)-21-[5-(4-cyclopropylpiperazin-1-yl)-2-[(1S)-1-methoxyethyl]pyridin-3-yl]-18,18-dimethyl-9,15-dioxo-22-(2,2,2-trifluoroethyl)-5,16-dioxa-2,10,22,28-tetraazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),20,23(27),24-tetraen-8-yl]acetamide; Zoldonrasib
- 用途
- 化学合成；作为新型口服RAS（ON）G12D选择性共价抑制剂，专门针对KRAS G12D突变的药物，通过共价结合的方式特异性抑制G12D突变蛋白的活性，阻断肿瘤细胞的生长和分裂；具有潜在的抗肿瘤和抑制肿瘤细胞增殖的活性，可用于胰腺癌的研究。
